| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | February 11, 2025 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - Neuraxis, INC (0001933567) (Issuer)
4 - Neuraxis, INC (0001933567) (Issuer)
4 - Neuraxis, INC (0001933567) (Issuer)
The new CPT code reflects the latest efficacious medical care available to patients, facilitating adoption and utilization.The assignment of a Category I CPT® code demonstrates a strong message to payers, both commercial and government, that there is now a path to consistent reporting and reimbursement for providers in the medical community. CARMEL, Ind., Jan. 08, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced that the Category I CPT code for Percutaneous Electrical Nerve Field Stimulation (PENFS) is now
CARMEL, Ind., Dec. 19, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation ("PENFS"). The coverage spans multiple states and represents approximately 45 million health plan members. NeurAxis' proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia (FD) including associ
CARMEL, Ind., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced that it has been awarded a Veterans Affairs (VA) Federal Supply Schedule (FSS) contract, effective December 1, 2025. The first product listed on the FSS is the IB-Stim®, a drug-free treatment for functional abdominal pain in patients 8 years and older. This contract award establishes NeurAxis as a federal contractor and creates a clear commercial pathway into the VA health system, which serves nearly 7 million active patients annually. T
4 - Neuraxis, INC (0001933567) (Issuer)
4 - Neuraxis, INC (0001933567) (Issuer)
4 - Neuraxis, INC (0001933567) (Issuer)
SCHEDULE 13G/A - Neuraxis, INC (0001933567) (Subject)
SCHEDULE 13G/A - Neuraxis, INC (0001933567) (Subject)
10-Q - Neuraxis, INC (0001933567) (Filer)
CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the appointment of Timothy Henrichs as Chief Financial Officer (CFO), effective February 5, 2024. As part of his appointment, Mr. Henrichs has resigned as an independent director on the board of NeurAxis (the "Board"). "We are thrilled to announce Tim as the new Chief Financial Officer of NeurAxis," said Brian Carrico, President and Chief Executive Officer of NeurAxis. "His extensive experience will be highly valuable
CARMEL, Ind., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its third quarter 2025, for the period ended September 30, 2025, on Tuesday, November 11, 2025, before market open. The Company has scheduled a conference call for the same day, Tuesday, November 11, 2025, at 9:00 am ET to review the results. Conference Call Details Date and Time: Tuesday, November 11, 2024, at 9:00am ET Live Webcast Information: Interested parties can access the conference call via a live we
CARMEL, Ind., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the second quarter 2025 for the period ended June 30, 2025. 2Q25 Financial highlights Revenues increased 46% year over year to $894 thousand in 2Q25 compared to $612 thousand in 2Q24.Operating expenses decreased 10% year over year in 2Q25 compared to 2Q24.Operating loss improved by 22% compared to the second quarter of 2024.Cash balance was $6 million as of June 30, 2025. The Company secured $5 million through an equity-on
CARMEL, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its second quarter 2025, for the period ended June 30, 2025, on Tuesday, August 12, 2025, before market open. The Company has scheduled a conference call for the same day, Tuesday, August 12, 2025, at 9:00 am ET to review the results. Conference Call Details Date and Time: Tuesday, August 12, 2024, at 9:00am ET Live Webcast Information: Interested parties can access the conference call via a live webcast, whi
SC 13D - Neuraxis, INC (0001933567) (Subject)
SC 13G - Neuraxis, INC (0001933567) (Subject)
SC 13G/A - Neuraxis, INC (0001933567) (Subject)